CBO Dr. Thomas Metz, PhD
Thomas Metz is scientifically interested in the design and profiling of conjugates and focuses on securing funding and establishing partnerships. Thomas is a molecular oncologist. He holds a diploma in molecular and cell biology from the University of Basel, earned his PhD at EMBL in Heidelberg working with avian leukemogenic retroviruses, and continued as a postdoc at the Walter & Elisa Hall Institute in Melbourne using murine retroviruses and p53-deficient mice. In 1994 he joined the newly formed oncology department at Boehringer Ingelheim in Vienna investigating EGFR and HDAC inhibitors and finally moving to Oncotest in Freiburg acquired by Charles River in 2015 where he held various leadership positions over a period of nearly 20 years.
CBO Dr. Thomas Metz, PhD
Thomas Metz is scientifically interested in the design and profiling of conjugates and focuses on securing funding and establishing partnerships. Thomas is a molecular oncologist. He holds a diploma in molecular and cell biology from the University of Basel, earned his PhD at EMBL in Heidelberg working with avian leukemogenic retroviruses, and continued as a postdoc at the Walter & Elisa Hall Institute in Melbourne using murine retroviruses and p53-deficient mice. In 1994 he joined the newly formed oncology department at Boehringer Ingelheim in Vienna investigating EGFR and HDAC inhibitors and finally moving to Oncotest in Freiburg acquired by Charles River in 2015 where he held various leadership positions over a period of nearly 20 years.